Calcium Channel Blockers

1. Front Matter

   Pages I-XIV

   PDF

2. Historical perspective: from early steps on calcium research to the identification of calcium antagonist prototypes and of the signaling functions of Ca2+

   • Théophile Godfraind

   Pages 1-9

3. Calcium channel blockers and calcium channels

   • Eric Ertel, Théophile Godfraind

   Pages 11-80

4. The action of calcium antagonists on Ca2+ movements in isolated vessels

   • Théophile Godfraind

   Pages 81-112

5. The tissue selectivity of calcium antagonists

   • Théophile Godfraind

   Pages 113-129

6. Acute haemodynamic effects of calcium channel blockers

   • Théophile Godfraind

   Pages 131-149

7. Calcium channels and regulation of vascular tone in hypertension

   • Théophile Godfraind

   Pages 151-159

8. Long-term effects of calcium antagonists

   • Théophile Godfraind

   Pages 161-179

9. Blood pressure-independent effects of calcium antagonists

   • Théophile Godfraind

   Pages 181-197

10. From early clinical studies to randomized controlled clinical trials

    • Théophile Godfraind

    Pages 199-236

11. Beyond the cardiovascular system

    • Théophile Godfraind

    Pages 237-254

12. Back Matter

    Pages 255-262

    PDF

The drugs named calcium channel blockers (CCBs) were initially termed cal­ cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba­ bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter­ mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2).

• Artherosclerosis
• Calcium Channel Blockers
• blood pressure
• calcium
• cardiovascular
• cardiovascular system
• clinical trial
• development
• hypertension
• research

• Université Catholique de Louvain, Bruxelles, Belgium

  Théophile Godfraind

Policies and ethics